Prostate cancer diagnostics company GenomeDx Biosciences has raised $25.4m in its third round of equity funding, which appears to have included existing backer Merck & Co.
GenomeDx Biosciences, a US-based genomic information company that counts pharmaceutical company Merck & Co as an investor, has secured $25.4m in new funding, according to a securities filing.
The investors in the round were not disclosed but signatories to the filing included Lawrence Senour, managing director of Merck subsidiary Merck Global Health Innovation, as well as company directors representing Aeris Capital, Tekla Capital Management and Baird Capital.
GenomeDx is developing cancer diagnostics products, and released Decipher Biopsy, a genomic test…
